Travis Steed
Stock Analyst at Barclays
(2.88)
# 1,393
Out of 4,810 analysts
85
Total ratings
42.65%
Success rate
7.14%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $205.71 | +26.88% | 8 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $270.27 | +18.40% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $127.96 | +17.22% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $67.80 | +25.37% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $69.87 | +28.81% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $14.88 | +115.05% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $28.38 | +58.56% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $11.06 | +306.87% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $353.42 | -10.87% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $255.47 | +15.47% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $16.06 | -0.37% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $17.03 | +93.78% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $101.97 | +56.91% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $490.13 | -35.73% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $5.41 | +47.87% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $11.90 | +110.08% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $15.08 | +463.66% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $67.39 | +85.49% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $84.22 | +72.17% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $94.27 | -45.90% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $50.98 | +243.27% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $16.73 | +222.77% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $102.13 | -78.46% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $205.71
Upside: +26.88%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $270.27
Upside: +18.40%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $127.96
Upside: +17.22%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $67.80
Upside: +25.37%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $69.87
Upside: +28.81%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $14.88
Upside: +115.05%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $28.38
Upside: +58.56%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $11.06
Upside: +306.87%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $353.42
Upside: -10.87%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $255.47
Upside: +15.47%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $16.06
Upside: -0.37%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $17.03
Upside: +93.78%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $101.97
Upside: +56.91%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $490.13
Upside: -35.73%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $5.41
Upside: +47.87%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $11.90
Upside: +110.08%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $15.08
Upside: +463.66%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $67.39
Upside: +85.49%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $84.22
Upside: +72.17%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $94.27
Upside: -45.90%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $50.98
Upside: +243.27%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $16.73
Upside: +222.77%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $102.13
Upside: -78.46%